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Abstract 
Objective: Schizophrenia has recently been associated with widespread white matter 
microstructural abnormalities, but the functional effects of these abnormalities remain unclear. 
Widespread heterogeneity of results from studies published to date preclude any definitive 
characterization of the relationship between white matter and cognitive performance in 
schizophrenia. Given the relevance of deficits in cognitive function to predicting social and functional 
outcomes in schizophrenia, we carried out a meta-analysis of available data through the ENIGMA 
Consortium, using a common analysis pipeline, to elucidate the relationship between white matter 
microstructure and a measure of general cognitive performance, intelligence quotient (IQ), in 
patients with schizophrenia and healthy participants.  
Methods: Our meta-analysis, the largest of its kind to date, included 760 patients with schizophrenia 
and 957 healthy participants from 11 participating ENIGMA-Consortium sites. For each site, principal 
component analysis was used to calculate both a global fractional anisotropy component (gFA), and 
a fractional anisotropy component for six long association tracts (LA-gFA) previously associated with 
cognition.  
Results: Meta-analyses of regression results indicate that gFA accounted for a significant amount of 
variation in cognition in the full sample (effect size, ES=0.27 CI=0.17-0.36), with similar effects sizes 
observed for both patient (ES=0.20, CI=0.05-0.35) and healthy participant subgroups (ES=0.32, 
CI=0.18-0.45). Comparable patterns of association were also observed between LA-gFA and 
cognition for the full sample (ES=0.28, CI=0.18-0.37), patient (ES=0.23, CI=0.09-0.38), and healthy 
participant subgroups (ES=0.31, CI=0.18-0.44).  
Conclusions: This study provides robust evidence that cognitive ability is associated with global 
structural connectivity, with higher fractional anisotropy associated with higher IQ. This association 
was independent of diagnosis; while patients tended to have lower FA and lower IQ than controls, 
the comparable size of effect in each group suggested a more general, rather than disease-specific, 







Schizophrenia is a leading cause of disability worldwide (1). Although this disability is typically 
characterised by clinical symptom severity, the cognitive deficits associated with the disorder 
strongly predict social and functional outcomes (2-4). These deficits are observed across multiple 
cognitive domains (5), suggesting that broad, rather than regionally specific, changes in brain 
function are likely to underpin these deficits. 
At a neural systems level, robust evidence of widespread differences in both white and gray matter 
has been demonstrated in large samples of patients with schizophrenia versus healthy participants 
(6, 7). Compared to healthy participants, people with schizophrenia show widespread thinning of 
cortical gray matter, and reduced cortical surface area, particularly in frontal and temporal lobe 
regions (7). Analysis of subcortical gray matter volumes similarly showed evidence of widespread 
differences, including bilateral volume abnormalities of the hippocampus, amygdala and thalamus 
(8). Recently, in the largest diffusion tensor imaging study of white matter abnormalities undertaken 
to date, widespread reductions in fractional anisotropy (FA) were observed for a majority (19/25) of 
tracts, with largest effects observed for global white matter FA, and more locally, in large tracts 
including the anterior corona radiata and corpus callosum (6). 
Taken collectively, these widespread abnormalities indicate a disease pathology reflective of 
generalised changes to the brains structural network and functions. This is consistent with the 
disconnectivity hypothesis of schizophrenia (9, 10), which suggests that functional impairments and 
disability results from abnormal and inefficient communication among distributed networks of brain 
regions (11, 12). This hypothesis would be further supported if these indices of disconnectivity could 
be directly related to variation in cognitive performance and functional outcomes, but well-powered 
studies in this area are currently lacking.  
To address this gap, here we aimed to examine the relationship between brain structure and 
cognitive function on a large, global scale. To do this, we carried out a meta-analysis of available 
data through the ENIGMA Consortium, using a common analysis pipeline, to elucidate the 
relationship between white matter microstructure and a measure of general cognitive performance, 
intelligence quotient (IQ), in patients with schizophrenia and healthy participants. We hypothesized 
that 1) a significant positive correlation would be observed between white matter microstructure 




Data for the current study was collected via the ENIGMA-Schizophrenia DTI working group and 
consisted of a sub-sample of participating sites in Kelly et al (6). Inclusion criteria for this current 
study was based on the availability of data processed using the ENIGMA DTI protocol, and measures 
of estimated IQ for each participant in a given dataset. The final sample consisted of 11 sites with 
both DTI and IQ, totalling 957 controls and 760 patients (detailed demographics in table 1). Each 
study sample had been assessed with participant’s written informed consent approved by local 
Institutional Review Boards. Individuals with bad-quality diffusion images were excluded from the 
analysis. 
Measurement of IQ 
IQ was calculated for healthy controls and patients with a confirmed diagnosis of schizophrenia. IQ 
The Wechsler Scale of Adult Intelligence (WAIS) was used to estimate IQ in all 11 studies. Ten sites 
calculated IQ based on the English version of the test (WAIS, 3rd edition); at the Madrid site, the 
Spanish version of the WAIS was used.  The WAIS consists of a battery of verbal and non-verbal 
subtests, scores of which are combined to derive a verbal IQ, performance IQ and full-scale (total) IQ 
score. Because not all sites had both verbal and performance score, our analyses were based 
exclusively on full-scale IQ scores. The number of subtests used to determine this full-scale score 
also varied between sites. Following previous large-scale multi-site analysis of IQ in schizophrenia by 
other consortia (e.g. COGENT) (13) IQ scores calculated for all sites were based on pro-rated subtest 
scores. For 9 of the 11 sites this was based on three or more subtests. At two sites IQ was calculated 
based on only two subtests being available for these samples (ASRB & MPRC).  
Image Acquisition and Processing 
Image data was acquired using site specific diffusion MRI sequences. Details of study type, scanner 
and acquisition parameters for each site are presented in supplementary table 1. For each site, 
preprocessing, including eddy current correction, echo-planar imaging-induced distortion correction, 
and tensor fitting, was carried out locally based on local protocols and procedures, and further 
informed by quality control pipelines available as part of the ENIGMA-DTI webpage 
(http://enigma.ini.usc.edu/protocols/dti-protocols) and NITRC (Neuroimaging Informatics Tools and 
Resources Clearinghouse). To correct for subject motion during image acquisition, preprocessing 
included the alignment of diffusion weighted images to the b=0 using linear image registration. 
Individual subject data with excessive motion was not included in this analysis. As per Kelly et al. (6), 
harmonization of preprocessing schemes was not enforced across sites to allow individual sites to 
use existing pipelines that may be more appropriate for their data acquisition. Following 
preprocessing, harmonized image analysis of DTI measure of FA was then conducted at each site in 
exactly the same manner using the ENIGMA-DTI protocol http://enigma.ini.usc.edu/protocols/dti-
protocols/). The ENIGMA-DTI protocol using TBSS (14) outputs averaged FA across all white matter 
tracts (listed in supplementary table 2). The TBSS output includes FA values for both right and left 
bilateral white matter tracts, and an average FA value based on the average FA from both 
hemispheres. Average FA values were used in for this analysis to minimize multiple comparisons and 
any potential issues of site-based left/right flipping which would limit interpretations of a lateralized 
analyses. 
Statistical Analysis 
Per-Site Analysis  
Calculation of FA is based on specific acquisition protocols including scanner make and model, 
diffusion sequence parameters, methods of tensor estimation models, and processing pipelines (15, 
16). To overcome this systematic limitation, preliminary analysis was carried out individually at each 
site to assess the association between white matter tract microstructure and estimates of IQ. Only 
then were summary statistics compared, thus removing the issue of variances across sites due to 
scanner or acquisition parameters.  
Per-Site Latent Fractional Anisotropy Factor Analysis 
To reduce the burden of multiple testing, we undertook principal components analysis of white 
matter tracts indexed by diffusion tensor imaging to index white matter. For each site separately, 
principal components analysis, implemented in SPSS, was used to derive an un-rotated first principal 
component, representing global white matter, termed ‘gFA’. In addition, six long association tracts, 
which have been previously associated with variation in IQ (see supplementary table 2), were also 
subjected to a principal components analysis, for which the first un-rotated principal component was 
again derived and termed ‘LA-gFA’.  Calculation of these components followed a similar approach to 
analyses carried out by Cox et al(17) and Penke et al(18). These studies reported that a latent factor 
explained a substantial portion of the variance in FA across all white matter tracts, whereby at an 
individual level, higher FA in a single tract predicted higher FA in all tracts. Generation of a single 
principal component for our analyses was designed to minimize the need to control for multiple 
comparisons across all white matter tracts. For each PCA, we examined scree plots and the 
extraction values to determine if tract FA values could be represented by a single latent factor. 
Comparable scree plots were observed for data across all sites for gFA, figure 1a. The loadings of 
each white matter tract on the first principal component are presented in supplementary data 2. FA 
variance explained by the first un-rotated component ranged from 44-70%, with a median of 56% 
(see supplementary table 3). Our second PCA analysis included FA of six long association tracts (LA-
gFA) based on white matter tracts previously associated with IQ in the literature (19-26). The six 
tracts included: the arcuate fasciculus, anterior limb of the internal capsule, superior longitudinal 
fasciculus, uncinate fasciculus, inferior fronto-occipital fasciculus, and the cingulate bundle. Like gFA, 
comparable scree plots were observed for data across all sites for LAgFA, figure 1b. 
The same PCA method was used to derive both global and long association latent factors for sites 
that included secondary diffusion parameters. Secondary parameters included mean diffusivity, 
radial diffusivity, and axial diffusivity.  
Per-Site Assessing the variance in IQ explained by white matter microstructure 
To calculate the variance in IQ explained by white matter microstructure, a hierarchical regression 
analysis was carried out on a site-by-site basis (using SPSS-24). After controlling for age and gender, 
the r-squared change was used to estimate the variance in IQ explained by either gFA or LA-gFA on 
IQ. These regression analyses were carried out for both the full sample, and for patients and controls 
separately, to allow determination of the effects of diagnosis.  
 
Meta-Analysis 
Comprehensive Meta-Analysis (https://www.meta-analysis.com/) software (statistical consultancy 
was not provided) was used locally to analyse summary data from all 11 contributing sites. The 
meta-analysis consisted of a two-level model, 1) a random effects model estimating the average 
effect size by combining the observed effect sizes across all studies in the sample; and 2) a mixed 
effects model incorporated diagnosis as a moderator variable to estimate the between-group 
variation and determine the effect of diagnosis on the observed association between white matter 
micorstructure and IQ. Secondary analysis was carried out to determine the moderating effects of 





Demographic & clinical information for the total ENIGMA samples of 957 healthy controls and 760 
patients with schizophrenia are presented in table 1. The mean age for patient and control samples 
across all sites was 36 (SD=9.1 and 10.1 respectively). With adolescent sites removed, the mean age 
for patient and control samples was 39 (SD=5.55 and 5.98 respectively). The patients were 70% male 
(males=535, females=225), a higher ratio compared to the control group (56% male; males=539, 
females=418), X2(1)=4.2, p=0.04. The mean IQ across patient samples was 97 (SD=16.47) and 113 
(SD=13.14) for healthy participants; see table 1. These values are somewhat higher than might be 
expected, especially for the patient group; a review of table 1 suggests that this difference is due to 
the IQ of patients in the ASRB dataset, which was the only dataset to have a mean patient IQ >100.  
Analysis of mean and standard deviation IQ across sites shows that on average, patients had 
significantly lower IQ compared to healthy controls (mean IQ HC=113 sd=5.82, Sz=97 sd=8.24, 
t(27)=5.94, p<0.001). The variance in IQ across sites was less in healthy controls compared to 
patients with schizophrenia (mean variance in IQ HC=13.14 sd=2.85, Sz=16.53 sd=3.31, t(27)=-2.94, 
p<0.01). The differences in IQ and variance in IQ remain significant with exclusion of the ASRB data, 
(mean IQ HC=110 sd=6.02, Sz=93 sd=6.89, t(27)=5.85, p<0.001, mean variance in IQ HC=14.33 
sd=2.65, Sz=17.50 sd=3.41, t(27)=-2.24, p<0.05). 
DTI and IQ  
The white matter tracts included in the gFA and LA-gFA princpal components analyses are outlined 
in supplementary table 2. The scree plots from the principal component analysis for each site 
provided evidence for a strong single latent factor for both global FA (gFA) and the six long 
association tracts (LA-gFA) in each case, figure 1. To determine the variances in IQ explained by 
global and long association white matter tracts, a regression analysis was carried out for gFA and LA-
gFA separately, controlling for both age and gender, in patients and healthy participants, on an site-
by-site basis. 
gFA analyses 
Meta-analytical results from the regression analysis for gFA showed that global white matter 
accounted for a significant amount of variance in IQ in the overall sample (3% variance, Hedges’ g 
ES=0.27, 95% CI=0.17-0.35, p<0.001, see figure 2, supplementary table 4).  
When considered separately, similar effects were observed in both the healthy participant subgroup 
(ES=0.32, 95% CI=0.18-0.45, p<0.001) and patient subgroup (0.20, 95% CI=0.05-0.35, p<0.01), figure 
3.  
A between group analsysis was undertaken to estimate whether the strenght of between white 
matter and IQ was different in patients versus healthy participants. No effect of diagnosis was 
observed (mixed model between-groups x2(1)=1.29, p=.26), indicating that the amount of variance in 
IQ explained by gFA was comparable between these groups.  
Given the differences in developmental stage of two samples that included adolescent participants 
(Oxford and Madrid) versus the result of the cohort, we re-ran the analysis excluding these two sites 
(healthy participants n=120, patients n=84). Removal of these adolescent datasets did not change 
the results of the meta-analysis - comparable findings were obtained for the sample overall (Hedges’ 
g ES=0.27, 95% CI=0.17-0.38, p<0.001), healthy participant subgroup (Hedges’ g ES=0.32, 95% 
CI=0.18-0.46, p<0.001), and patient subgroup (Hedges’ g ES=0.21, 95% CI=0.06-0.37, p<0.01). 
Furthermore, we observed higher IQ in the patient group across the ASRB sites. Again, removing this 
site from the analysis did not change the observed effect size for the healthy participant subgroup 
(Hedges’ g ES=0.33, 95% CI=0.18-0.48, p<0.001) and patient subgroup (Hedges’ g ES=0.21, 95% 
CI=0.006-0.40, p<0.05). 
Due to the variance in effect size across sites, a leave-one-out analysis was carried out to determine 
if the observed results were driven by single sites. The leave-one-out cross validation requires 
multiple iterations of the meta-analysis on all the data except for the one site excluded per iteration 
(n-1). A meta-analysis was then carried out on the mean and standard deviation of the observed 
effect size for each iteration, with one study ommited for the analysis. The results of gFA leave-one-
out analysis remain significant for each iteration, with the mean ES=0.25, range=0.18-0.34 for the 
full sample, ES=0.29, range=0.26-0.34 for healthy controls, and ES=0.20, range=0.18-0.22 for 
patients, figure 4a, supplementary table 7. 
LA-gFA analyses 
To specifically test for a relationship between cognition and long association fibre tracts previously 
hypothesised in the literature to be involved in cognitive performance, a single latent FA factor was 
generated for the six long association tracts, identified above, and termed LA-gFA. Similarly to global 
white matter microstructure, LA-gFA accounted for a significant amount of variance in IQ in the full 
sample (3.5% variance, Hedges’ g ES=0.28, 95% CI=0.18-0.37, p<0.001), figure 3. This significant 
effect for LA-gFA was also observed separately in the healthy participant subgroup (Hedges’ g 
ES=0.31, 95% CI=0.18-0.44, p<0.001) and patient subgroup (Hedges’ g ES=0.23, 95% CI=0.09-0.38, 
p<0.01). The meta-analytic results for LA-gFA are outlined in supplementary table 5. The between-
sample LA-gFA meta-analysis results again indicate that there was no significant difference in the 
observed effect size between the healthy participant and patient subgroups (x2(1)=0.55, p=0.46). As 
with gFA, these results did not change after removing adolescent populations (Hedges’ g overall 
sample ES=0.29 95% CI=0.18-0.40, healthy participant ES=0.33 95% CI=0.19-0.47, and patient 
ES=0.23 95% CI=0.08-0.39 subgroups), with no observed diagnostic effect (x2(1) =0.85, p=0.36). 
Similarly, removal of the ASRB data did not significantly change the effect size for both healthy 
participants (Hedges’ g ES=0.32, 95% CI=0.18-0.47, p<0.001), and patients (Hedges’ g ES=0.27, 95% 
CI=0.07-0.47, p<0.01), with no significant diagnostic effect (x2(1) =0.18, p=0.68). The comparable 
findings between gFA and LA-gFA are perhaps not surprising given the strong positive correlation 
between these components (see supplementary table 6). Given this, to determine whether the 
effects observed for gFA were driven by long association tracts, we re-calculated the gFA component 
to exclude the six long association tracts on which the LA-gFA was based. The results obtained were 
largely unchanged, both for the whole group analysis (3% variance, Hedges’ g ES=0.29, 95% CI=0.19-
0.39, p<0.001) and separately for the healthy participant subgroup (Hedges’ g ES=0.30, 95% CI=0.17-
0.44, p<0.001) and patient subgroup (Hedges’ g ES=0.27, 95% CI=0.13-0.42, p<0.001).  Finally, as per 
the gFA analyses, a leave-one-out analysis was also undertaken.  Here again, the results remain 
unchanged (mean ES=0.27, range=0.21-0.33 for the full sample, ES=0.31, range=0.29-0.33 for 
healthy controls, and ES=0.23, range=0.21-0.27 for patients, figure 4b, supplementary table 8).  
Assocation between gFA/LAgFA and IQ in males & females 
To determine the effects of gender on the relationship between white matter and IQ, a further 
meta-analysis was carried out. Similar results were observed between males and females in gFA 
(males  Hedges’ g ES=0.36, CI=0.23-0.48, p<0.001, females ES=0.39, CI=0.22-0.55, p<0.001), with no 
significant difference, x2(1)=0.088, p=0.77 (supplementary figure 1a, supplementary table 9). For 
gFA, female patients had the largest observed effect size, although this was not significantly 
different compared to male patients (female Sz Hedges’ g ES=0.45, CI=0.25-0.65, p<0.001, male HC 
ES=0.25, CI=0.07-0.43, p<0.01, x2(1)=2.14, p=0.14 ). Similarly, there was no effect of gender in the 
healthy control sample (female HC Hedges’ g ES=0.27, CI=0.06-0.48, p<0.05, male HC ES=0.39, 
CI=0.20-0.47, p<0.001, x2(1)=0.68, p=0.14). 
Likewise for LAgFA there was no significant difference in the observed effect sizes for males and 
females (males Hedges’ g ES=0.33, CI=0.21-0.46, p<0.001, females ES=0.37, CI=0.20-0.53, p<0.001, 
supplementary figure 1b, supplementary table 10). Female patients had the largest observed effect 
size for LA-gFA, although this was not significantly different compared to male patients (female Sz 
Hedges’ g ES=0.39, CI=0.10-0.68, p<0.01, male HC ES=0.19, CI=0.01-0.37, p<0.01, x2(1)=1.35, p=0.26). 
Similarly, there was no effect of gender in the healthy control sample (female HC Hedges’ g ES=0.31, 
CI=0.10-0.52, p<0.01, male HC ES=0.38, CI=0.20-0.57, p<0.001, x2(1)=0.27, p=0.60). 
 
Association between diffusion MRI secondary parameters and IQ 
Secondary diffusion MRI parameters were available for a subset of sites (ASRB, Edinburgh, Dublin, 
HUBIN, MCPR, Galway) which included 397 healthy controls and 467 patients with schizophrenia. 
Meta-analysis, reported in supplementary table 11, show that radial diffusivity had the largest effect 
size for both global and long association tracts across the full sample (gRD ES=0.33, CI=0.13-0.52, 
p=0.001 and LA-gRD ES=0.34, CI=0.08-0.0.52, p=0.01). Standardized Beta coefficients from this 






This study sought to characterise the relationship between white matter microstructure and IQ, and 
to compare this association between patients with schizophrenia and healthy participants. We 
carried out a meta-analysis of datasets from participating ENIGMA groups, analysed according to a 
common analysis pipeline, to assess the relationship between white matter microstructure and IQ in 
patients with schizophrenia and healthy participants. Our findings indicated that global white matter 
microstructure accounted for a significant amount of variation in IQ (ES=0.27), both in patients with 
schizophrenia and healthy participants, with the size of association observed to be comparable 
between groups. Comparable results were obtained based on either global white matter values 
(ES=0.27), or six regional association white matter tracts (ES=0.28) which connect frontal, parietal 
and temporal lobes and previously hypothesised as involved in IQ. These findings were unequivocal, 
supporting the value of meta-analysis based on harmonized pipelines and large datasets.  
The results of this ENIGMA meta-analysis consistently showed a pattern of significant (albeit 
modest) associations between white matter FA and IQ in both patients and healthy participants. 
Robust evidence of association between variation in IQ and variation in white matter structural 
connectivity was found, with similar effect sizes observed in patients and healthy participant 
cohorts. A landmark review carried out by Deary et al (24) suggested that intelligence is regulated by 
a widely distributed complex neurological network. Our study provides empirical evidence for this 
claim in the largest IQ study undertaken to date, consistent with previous studies linking white 
matter microstructure to processing speed (a cognitive variables highly correlated with IQ; (18, 22, 
27). Collectively, these results indicate that global white matter provides a neural network to 
support the functional cortical communication required for general cognitive performance. The 
similar effect sizes observed in both global and long association fibre-based measures of FA 
underline the nature of this relationship as a global phenomenon rather than a regionally specific 
association.  
Previous studies had focused mainly on individual white matter tracts, including fronto-parietal 
white matter (22, 28), cingulate (21, 29, 30), uncinate fasciculus (20), fornix (19), and corpus 
callosum (31). A significant positive correlation between IQ in fronto-parietal white matter (28), 
uncinate fasciculus (20), and cingulate bundle (21, 30) was frequently observed in schizophrenia, 
with negative or no significant associations reported in healthy participants. The heterogeneity of 
results between studies was most likely due to small sample sizes, and methodological differences 
that limited replicability of results (19-22, 28-32). Here we have overcome the limitation of small 
sample sizes by using a harmonized processing DTI pipeline and statistical analysis on over 1,700 
participants. We also conclude that the findings reported here are not driven any single site (based 
on the leave-one-out analyses for both gFA and LA-gFA) and can therefore be expected to generalize 
to independent samples. In addition, these findings did not appear to be explained by the higher 
proportion of males in the total sample as we have shown that the association between white 
matter microstructure and IQ is not significantly different between males and females.  
The relationship between white matter microstructure and IQ in patients versus controls 
Our results indicate that the relationship between structural connectivity and higher cognitive 
function is broadly comparable between patient and control groups, with no differences in effect 
sizes observed. We (6) previously reported widespread white matter deficits in schizophrenia that 
spanned 19 white matter tracts and hypothesised that in schizophrenia these may predict deficits in 
cognitive performance more strongly than for variance in cognitive performance in the normal 
population, as suggested by previous, albeit smalls scale, studies (20-22, 28, 30). By contrast, 
however, we observed similar effects between patients and healthy participants. This finding 
suggests that individual variances of low to high efficient transfer of information across white matter 
tracts is associated with a range of lower to higher cognitive functioning, irrespective of diagnosis. As 
such, patients with schizophrenia occupied the lower quadrant of the correlation matrix between 
white matter microstructure and IQ. We speculate, based on these results, that a common 
neurodevelopment process and cytoarchitecture predicts outcomes in cognitive performance, 
independent of a clinical diagnosis. However, future studies of the genetic and neurodevelopment 
associations between schizophrenia, white matter, and measures of cognitive ability will be needed 
to address these questions.  
Patients in the ASRB dataset had an average IQ value of 105. Generally, patients with schizophrenia 
consistently demonstrate a medium-sized impairment in IQ (33), with an 8-point IQ deficit observed 
in the premorbid stage (33), and 14-21 point IQ deficit amongst those with first episode and chronic 
schizophrenia (34-36). Furthermore, lower IQ is associated with increased risk of schizophrenia (37). 
To determine if the ASRB patient IQ (above average norms) was confounding any diagnostic effect, 
the analysis was re-run without this data. The effect size observed for the patient group, for both 
gFA and LA-gFA, did not significantly change, supporting the hypothesis that the association 
between white matter and IQ is independent of diagnosis.  
Kelly et al. reported patients with schizophrenia had significantly higher mean diffusivity and radial 
diffusivity across the majority of white matter tracts. Higher radial diffusivity, which underlies 
changes in fractional anisotropy, is indicative of microstructural alterations. Specifically, it provides 
an index of diffusion in an orientation perpendicular to a white matter tract. Our findings indicate 
both higher FA, and related to this, lower RD is associated with higher cognitive function in both 
patients and controls. Similar effect sizes were observed for the association between radial 
diffusivity and IQ in both patients and controls. While the precise biological interpretation of 
changes in radial diffusivity must be done cautiously, however previous studies have speculated that 
radial diffusivity is associated with demyelination (38). Increased radial diffusivity associated with 
demyelination supports our findings that efficient global structural connectivity facilitates higher 
cognitive function, independent of diagnosis.  
Strengths & Limitations 
In this study, we adopted a ‘prospective’ meta-analytic approach that analysed the relationship 
between IQ and DTI based on a well validated and harmonised ENIGMA DTI analysis pipeline carried 
out in a large sample of 1,717 participants. Doing so overcomes many of the significant limitations in 
previous studies by minimising sources of heterogeneity, and potential for consequent false 
positive/negatives findings. However, future analysis could also include methods to incorporate 
harmonised measures of environmental factors, such as educational level, socio-economic status, 
general health and lifestyle, which may impact cognitive outcomes. ENIGMA DTI pipelines 
incorporate tract based spatial statistics (14), which is a widely used method for voxel-based analysis 
of white matter tracts. Although tensor based limitations have been widely reported, i.e. it does not 
capture all information on white matter microstructure, such as myelination, axonal packing density, 
or neuro-inflammation. DTI remains the most consistently used method in diffusion MRI analysis, 
and pending a general consensus on non-tensor based processing methods that are void of potential 
artifacts, the analysis carried out here is the most advanced that definitively supports the structural 
underpinnings of cognitive performance. During image preprocessing, DTI data was corrected for 
motion induced artifacts, however studies have shown that some white matter tracts may be more 
sensitive to microscopic head movements which may produce spurious group differences (39). To 
overcome motion induced variances, previous single site studies have included a metric of motion as 
a covariate in the analysis (39, 40). Further development of these methods would be required for 
implementation in multi-site analysis within large consortia.  
Here, we used a principal component analysis to derive components for global and long association 
tract FA values. While this eliminates the need for multiple comparison correction, it reduces the 
ability to detect a possible, albeit unlikely, association between cognition and specific individual 
white matter tracts. Previous studies used similar PCA analyses to assess the relationship between 
global neural underpinnings of functional measures (17, 41).  
While we have unequivocally shown here a relationship between white matter and cognitive ability, 
further studies are necessary to determine the associations with gray matter measures. Although 
this has been more widely studied in the literature, study sample sizes were still limited and 
methodological issues make it difficult to summarize the findings. The latest ENIGMA study (Grasby 
et al., under review) shows a strong overlap between the genetic influences on cortical surface area 
and educational attainment. Similar analysis to that carried out here may help identify cortical 
regions associated with cognitive deficits observed in schizophrenia. Finally, future analysis is also 
required to determine if the associations reported here generalise to other psychiatric disorders, 
although the comparability between patients and controls observed here suggests that this is likely. 
 
Conclusion 
This study provides robust evidence that cognitive ability is associated with global structural 
connectivity, with more efficient white matter microstructure associated with higher IQ. This 
association was independent of diagnosis: across the distribution of scores on FA and IQ measures, 
patients tended to have lower FA and lower IQ, healthy participants tended to have higher FA and 
higher IQ, and the effects size of these associations between FA and IQ were comparable between 
groups. These findings suggest that a general association between lower FA and lower IQ is likely, 
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Tables & Figures 
 
Tables 
Table 1. Demographical data collected from 11 collaborating ENIGMA-Schizophrenia DTI working 
group sites. 
 
Figures Attached Seperately 
Figure Legends 
Figure 2. Forest plot for gFA meta-analysis (Hedges’ g and 95% CI). There was no significant 
difference between the observed effect size in patients compared to controls, x2(1)=1.3, p=0.26. ┼ 
indicates Hedges’ g subgroup summaries for patients and control groups separately, ♦ represents 
summary statistics for the full sample. 
Figure 3. Forest plot for LA-gFA meta-analysis (Hedges’ g and 95% CI). There was no significant 
difference between the observed effect size in patients compared to controls, x2(1)=0.55, p=0.46. ┼ 
indicates Hedges’ g subgroup summaries for patients and control groups separately, ♦ represents 
summary statistics for the full sample. 
Figure 4. Leave-one-out meta-analysis for a gFA and b LAgFA. For both, 11 separate meta-analyses 
were carried out with n-1 site. The mean Hedges’ g effect size was taken for each meta-analysis with 
one site omitted for each iteration. The study name corresponds to the results when this site was 
omitted from the analysis. The association between both gFA and LAgFA with IQ remains significant 
for each iteration indicating that the results are not driven by a specific site. 
 
 
















Mean Age Mean IQ 
  
sample size st. dev st. dev 
    HC SZ HC SZ HC SZ 
ASRB1 Male 16 89 40 39 118 100 
 
Female 17 32 14.1 10.9 11 17 
ASRB2 Male 41 54 41 38 115 105 
 
Female 38 31 13.8 10.4 11 13 
ASRB3 Male 9 12 44 42 113 112 
 
Female 9 5 13.6 8.7 12 12 
ASRB4 Male 15 28 37 39 120 101 
 
Female 14 11 13.7 10.4 8 17 
ASRB5 Male 18 42 40 40 118 105 
 
Female 20 22 13.9 10.4 13 14 
Edin Male 19 17 37 35 116 105 
 
Female 17 11 15.2 10.1 11 16 
Dublin males 27 22 35 44 118 91 
 
















HUBIN male 20 22 54 52 104 88 
 
female 12 5 8.96 7.5 18 18 
MPRC male 26 21 39 37 99 91 
 
female 46 10 14.3 12.5 18 15 
TOP male 137 18 32 29 113 97 
 
female 99 11 7.6 8.4 11 15 
MCIC males 72 69 31 33 115 98 
 
females 41 26 10.9 11.4 14 19 
COBRE males 62 72 39 39 111 99 
 
females 22 22 11.9 13.8 13 17 
Madrid male 53 31 13 17 111 80 
 
female 31 10 4.3 3.3 15 25 
Oxford males 24 18 13 14 109 91 
 
females 19 18 1.2 1.4 13 15 
  
957 760 36 36 113 97 
    
10.1 9.1 6 8 
 
Table 1. Data collected from 11 collaborating ENIGMA-Schizophrenia DTI working group. The final 
sample size consisted of 1049 healthy participants and 798 patients with schizophrenia. *indicates 
sites with data from adolescent participants. ASRB=Australian Schizophrenia Research Bank, 
EDIN=Edinburgh, HUBIN=Human Brain Informatics, MPRC=Maryland Psychiatric Research Center, 























The relationship between white matter microstructure and general cognitive ability in patients 
with schizophrenia and healthy participants in the ENIGMA consortium 
Supplementary Material 
Tables 
Supplementary Table 1. DTI acquisition protocols for contributing ENIGMA-Schizophrenia working 
group site 
Supplementary Table 2. List of white matter tracts included in the principal component analysis to 
derive a single latent component for global fractional anisotropy (gFA) and six long association tracts 
(LA-gFA). 
Supplementary Table 3. Total percent variance explained for gFA and LA-gFA first un-rotated 
principal component 
Supplementary table 4. gFA meta-analysis results using a random effects model. 
Supplementary table 5. LAgFA meta-analysis results using a random effects model. 
Supplementary Table 6. Pearson’s correlation coefficient for gFA and LA-gFA components. 
cc=correlation coefficient. 
Supplementary table 7. Leave-one-out meta-analysis for gFA. 
Supplementary table 8. Leave-one-out meta-analysis for LAgFA. 
Supplementary table 9. Meta-analysis results for gFA and IQ in males & females. 
Supplementary table 10. Meta-analysis results for LAgFA and IQ in males & females. 
Supplementary table 11. Meta-analysis results for secondary diffusion MRI parameters. 
Supplementary table 12. Per-Site Regression Standardized Beta Coefficients for secondary diffusion 
MRI parameters.  
Figures 
Supplementary Figure 1. Sex dependent meta-analysis results for a gFA and b LAgFA. There was no 
significant difference in the observed Hedges’ g effect size for gFA between males (ES=0.35, CI=0.23-
0.48) and females (ES=0.39, CI=0.22-0.55), x2(1)=0.09 p=0.77. Similarly for LAgFA there was no 
significant difference in the observed Hedges’ g effect size for males (ES=0.33, CI=0.21-0.46) and 
females (ES=0.37, CI=0.20-0.53), x2(1)=0.11 p=0.74. 
 
 
Supplementary Table 1. DTI acquisition protocols for contributing ENIGMA-Schizophrenia working 
group site. ASRB=Australian Schizophrenia Research Bank, EDIN=Edinburgh, HUBIN=Human Brain 
Informatics, MPRC=Maryland Psychiatric Research Center, MCIC=MIND Clinical Imaging Consortium, 
















ASRB 1 Siemens Avanto 1.5T 1 2.4x2.4x2.4 64 at b 
=1000 
1 
ASRB 2 Siemens Avanto 1.5T 1 2.4x2.4x2.4 64 at b 
=1000 
1 
ASRB 3 Siemens Avanto 1.5T 1 2.4x2.4x2.4 64 at b 
=1000 
1 
ASRB 4 Siemens Avanto 1.5T 1 2.4x2.4x2.4 64 at b 
=1000 
1 





3T 1 2.2x2.5x2.5 56 at 
b=1000 
6 




1.5T 1 2.5x2.5x2.5 64 at 
b=1300 
7 





MPRC Siemens Alegra 3T 1 1.7×1.7×4.0 12 at 
b=1000 
8 
TOP GE 3T 1 2x2x2.5 30 at 
b=1000 
1 
MCIC 1 Siemens Sonata 1.5T 1 2x2x2 12 at 
b=1000 
1 
MCIC 2 Siemens Trio 3T 1 2x2x2 6 at b=1 00 1 
MCIC 3 Siemens Trio 3T 1 2x2x2 12 at 
b=1000 
1 
MCIC 4 Siemens Sonata 1.5T 1 2x2x2 60 at b=700 1 
COBRE Siemens TIM Trio 3T 2 2x2x2 30 at b=800 5 
Madrid 
1 
Philips Intera 1.5T 1 1.75x1.75x2 15 at b=800 1 
Madrid 
2 
Philips Intera 1.5T 2 2x2x2 32 at b=800 1 
Madrid 
3 
Philips Intera 1.5T 1 2x2x2 64 at 
b=1000 
1 




Abbreviation White Matter Tract 
Avg-FA Average FA 
GCC Genu of Corpus Callosum 
BCC Body of Corpus Callosum 
SCC Splenium of Corpus Callosum 
FX Fornix 
ALIC Anterior Limb of the Internal Capsule* 
IC Internal Capsule 
CC Corpus Callosum 
ACR Arcuate Fasciculus* 
SCR Superior Corona Radiata 
PCR Posterior Corona Radiata 
CR Corona Radiata 
PTR Posterior Thalamic Radiation 
SS Sagittal stratum 
EC External capsule 
CGC Cingulum (cingulate gyrus)* 
SLF Superior Longitudinal Fasciculus* 
SFO Superior Fronto-Occipital Fasciculus 
FX-ST Fornix/Stria Terminalis 
IFO Inferior Fronto Occipital Fasciculus* 
UNC Uncinate Fasciculus* 
 
Supplementary table 2. The 19 white matter tracts which were reported in Kelly et al to have 
significantly reduced FA in patients with schizophrenia compared to controls. The ENIGMA-DTI 
protocol outputs average FA for each bilateral white matter tract. The present analysis combined FA 
from both hemispheres for the tracts listed above to avoid any potential issues of left/right flipping. 
gFA was computed using a principal component analysis of the tracts listed above. * identifies tracts 









ASRB-1 58 49 
ASRB-2 55 51 
ASRB-3 57 52 
ASRB-4 56 51 
ASRB-5 50 44 
EDIN 61 57 
Dublin 52 46 
Galway 63 64 
HUBIN 48 50 
MPRC 67 67 
TOP 44 43 
MCIC 52 42 
COBRE 58 57 
Madrid 55 54 
Oxford 70 67 
Median 56 51 
Range 44-70 42-67 
 
Supplementary Table 3. Total percent variance explained for the first unrotated component 
representing global fractional anisotropy (gFA) and the first unrotated component representing six 





Site n Hedge's g CI Lower CI Upper p Z 
HC 
ASRB-1 33 0.14 -0.58 0.86 0.71 0.38 
ASRB-2 79 0.32 -0.13 0.78 0.16 1.39 
ASRB-3 18 0.12 -0.89 1.13 0.82 0.23 
ASRB-4 29 0.28 -0.49 1.06 0.47 0.72 
ASRB-5 38 0.28 -0.39 0.95 0.41 0.82 
EDIN 36 0.21 -0.48 0.89 0.56 0.59 
Dublin 60 0.00 -0.52 0.52 1.00 0.00 
HUBIN 32 0.09 -0.64 0.82 0.81 0.23 
MCPR 72 0.39 -0.09 0.87 0.11 1.60 
TOP 236 0.38 0.12 0.64 0.00 2.85 
MCIC 113 0.48 0.10 0.87 0.01 2.47 
COBRE 84 0.40 -0.05 0.84 0.08 1.76 
Madrid 84 0.32 -0.12 0.76 0.15 1.44 
Oxford 43 0.18 -0.45 0.80 0.58 0.55 
HC mean 957 0.32 0.18 0.45 <0.001 4.72 
SZ 
ASRB-1 121 0.23 -0.14 0.59 0.22 1.23 
ASRB-2 85 0.04 -0.40 0.47 0.87 0.16 
ASRB-3 17 0.31 -0.75 1.37 0.57 0.57 
ASRB-4 39 0.20 -0.46 0.85 0.56 0.59 
ASRB-5 64 0.34 -0.17 0.84 0.20 1.29 
EDIN 28 1.57 0.55 2.58 0.00 3.02 
Dublin 28 0.30 -0.50 1.09 0.46 0.74 
Galway 25 0.36 -0.49 1.21 0.40 0.83 
HUBIN 27 0.17 -0.63 0.98 0.67 0.42 
MCPR 31 0.11 -0.64 0.85 0.78 0.28 
TOP 29 0.28 -0.50 1.05 0.48 0.70 
MCIC 95 0.11 -0.30 0.52 0.60 0.52 
COBRE 94 0.13 -0.29 0.54 0.55 0.60 
Madrid 41 0.11 -0.53 0.74 0.74 0.33 
Oxford 36 0.06 -0.62 0.75 0.86 0.18 
SZ mean 760 0.20 0.05 0.35 <0.01 2.66 
Overall 
 
1717 0.27 0.17 0.36 <0.001 5.29 
 
Supplementary table 4. gFA meta-analysis results using a random effects model. gFA accounted for 
a significant amount of variance in IQ in the full sample (average Hedges’ g ES=0.27), healthy 
participant (ES=0.32) and patient (ES=0.20) groups. HC=healthy control, SZ=patients with 




Site n Hedge's g CI Lower CI Upper p Z 
HC 
ASRB-1 33 0.04 -0.66 0.74 0.91 0.11 
ASRB-2 79 0.46 0.01 0.92 0.05 1.99 
ASRB-3 18 0.18 -0.79 1.15 0.71 0.37 
ASRB-4 29 0.06 -0.69 0.81 0.87 0.16 
ASRB-5 38 0.19 -0.47 0.84 0.57 0.56 
EDIN 36 0.06 -0.61 0.73 0.86 0.18 
Dublin 60 0.21 -0.31 0.72 0.43 0.79 
HUBIN 32 0.94 0.15 1.73 0.02 2.34 
MCPR 72 0.18 -0.29 0.65 0.46 0.74 
TOP 236 0.37 0.11 0.63 0.00 2.81 
MCIC 113 0.48 0.10 0.87 0.01 2.49 
COBRE 84 0.35 -0.08 0.79 0.11 1.58 
Madrid 84 0.13 -0.31 0.56 0.57 0.57 
Oxford 43 0.22 -0.39 0.83 0.49 0.70 
HC mean 957 0.31 0.18 0.44 <0.0001 4.65 
SZ 
ASRB-1 121 0.38 0.02 0.75 0.04 2.06 
ASRB-2 85 0.01 -0.42 0.44 0.97 0.04 
ASRB-3 17 0.23 -0.77 1.24 0.65 0.46 
ASRB-4 39 0.18 -0.47 0.82 0.59 0.54 
ASRB-5 64 0.09 -0.41 0.58 0.73 0.35 
EDIN 28 1.58 0.60 2.56 0.00 3.16 
Dublin 28 0.21 -0.56 0.97 0.60 0.53 
Galway 25 0.12 -0.69 0.93 0.77 0.30 
HUBIN 27 0.19 -0.59 0.96 0.64 0.47 
MCPR 31 0.54 -0.21 1.29 0.16 1.42 
TOP 29 0.00 -0.75 0.75 1.00 0.00 
MCIC 95 0.34 -0.07 0.75 0.10 1.63 
COBRE 94 0.06 -0.34 0.47 0.76 0.31 
Madrid 41 0.35 -0.28 0.98 0.28 1.08 
Oxford 36 0.11 -0.56 0.78 0.75 0.32 
SZ mean 760 0.23 0.09 0.38 <0.0001 3.13 
Overall 
 
1717 0.28 0.18 0.37 <0.0001 5.56 
 
Supplementary table 5. LAgFA meta-analysis results using a random effects model. LA-gFA 
accounted for a significant amount of variance in IQ in the full sample (average Hedges’ g ES=0.28), 
healthy participant (ES=0.31) and patient (ES=0.23) groups. HC=healthy control, SZ=patients with 


































Mean CI Lower CI Upper p z 
HC 
ASRB 0.30 0.17 0.42 <0.001 4.75 
Cobre 0.28 0.16 0.39 <0.001 4.73 
Dublin 0.34 0.22 0.45 <0.001 5.55 
EDIN 0.29 0.18 0.40 <0.001 5.12 
Galway 0.29 0.18 0.40 <0.001 5.15 
HUBIN 0.30 0.19 0.41 <0.001 5.19 
Madrid 0.29 0.17 0.40 <0.001 4.88 
MCIC 0.27 0.15 0.38 <0.001 4.49 
MCPR 0.28 0.17 0.40 <0.001 4.85 
Oxford 0.29 0.18 0.40 <0.001 5.14 
Top 0.26 0.14 0.39 <0.001 4.10 
HC mean 0.29 0.25 0.32 <0.001 16.28 
SZ 
ASRB 0.21 0.04 0.37 <0.01 2.43 
Cobre 0.21 0.08 0.35 <0.01 3.08 
Dublin 0.20 0.06 0.33 <0.01 2.92 
EDIN 0.18 0.05 0.30 <0.01 2.67 
Galway 0.20 0.07 0.33 <0.01 3.00 
HUBIN 0.20 0.07 0.33 <0.01 3.07 
Madrid 0.21 0.08 0.34 <0.01 3.13 
MCIC 0.22 0.08 0.35 <0.01 3.12 
MCPR 0.21 0.08 0.34 <0.01 3.12 
Oxford 0.21 0.08 0.34 <0.01 3.16 
Top 0.20 0.07 0.33 <0.01 3.03 
SZ mean 0.20 0.16 0.24 <0.001 9.88 
Overall 
 
0.25 0.23 0.28 <0.001 18.78 
 
 
Supplementary table 7. Leave-one-out meta-analysis for gFA. For each meta-analysis iteration a 
single site was omitted to determine if significant findings were driven by a single site. The leave-
one-out analysis indicates that for each site omitted the results remain significant with the mean 
Hedges’ g ES=0.25 for the full sample, ES=0.20 for patients, and ES=0.29 for healthy participants, 





Mean CI Lower CI Upper p z 
HC 
ASRB 0.32 0.20 0.44 <0.001 5.20 
Cobre 0.31 0.19 0.42 <0.001 5.29 
Dublin 0.33 0.21 0.44 <0.001 5.40 
EDIN 0.32 0.21 0.43 <0.001 5.60 
Galway 0.31 0.20 0.42 <0.001 5.55 
HUBIN 0.29 0.17 0.40 <0.001 5.04 
Madrid 0.33 0.21 0.44 <0.001 5.61 
MCIC 0.29 0.17 0.40 <0.001 4.88 
MCPR 0.32 0.21 0.43 <0.001 5.53 
Oxford 0.31 0.20 0.42 <0.001 5.50 
TOP 0.29 0.17 0.41 <0.001 4.58 
HC mean 0.31 0.27 0.34 <0.001 17.56 
SZ 
ASRB 0.26 0.09 0.43 <0.001 2.96 
Cobre 0.25 0.12 0.39 <0.001 3.67 
Dublin 0.23 0.10 0.36 <0.001 3.47 
EDIN 0.20 0.07 0.33 <0.001 3.08 
Galway 0.23 0.10 0.36 <0.001 3.57 
HUBIN 0.23 0.10 0.36 <0.001 3.53 
Madrid 0.22 0.09 0.35 <0.001 3.38 
MCIC 0.21 0.08 0.35 <0.001 3.11 
MCPR 0.22 0.09 0.35 <0.001 3.37 
Oxford 0.24 0.11 0.37 <0.001 3.58 
TOP 0.24 0.11 0.37 <0.001 3.64 
SZ mean 0.23 0.19 0.27 <0.001 11.27 
Overall 
 
0.27 0.25 0.30 <0.001 20.64 
 
Supplementary table 8. Leave-one-out meta-analysis for LAgFA. For each meta-analysis iteration a 
single site was omitted to determine if significant findings were driven by a single site. The leave-
one-out analysis indicates that for each site omitted the results remain significant with the mean 
Hedges’ g ES=0.27 for the full sample, ES=0.23 for patients, and ES=0.31 for healthy participants, 
p<0.001. HC=healthy control, SZ=patients with schizophrenia, CI=95% confidence intervals. 
 
 
Site Hedge's g CI Lower CI Upper p z 
Female 
ASRB-1 0.52 -0.08 1.12 0.09 1.71 
ASRB-2 0.21 -0.28 0.69 0.40 0.84 
ASRB-3 0.27 -0.93 1.46 0.66 0.44 
ASRB-4 0.00 -0.84 0.84 1.00 0.00 
ASRB-5 0.45 -0.19 1.10 0.17 1.37 
EDIN 0.26 -0.60 1.12 0.55 0.59 
Dublin 0.06 -0.59 0.72 0.85 0.19 
HUBIN 1.00 -2.52 4.52 0.58 0.56 
MCPR 0.32 -0.74 1.39 0.55 0.59 
TOP 0.17 -0.37 0.71 0.55 0.60 
MCIC 0.73 0.33 1.13 <0.001 3.54 
COBRE 0.95 0.41 1.50 <0.001 3.43 
Madrid 0.21 -0.41 0.82 0.51 0.66 
Oxford 0.12 -0.51 0.76 0.70 0.38 
Oxford 0.22 -0.45 0.90 0.52 0.65 
mean 0.39 0.22 0.55 <0.001 4.57 
Male 
ASRB-1 0.32 -0.08 0.71 0.11 1.58 
ASRB-2 0.29 -0.12 0.70 0.17 1.38 
ASRB-3 0.12 -0.80 1.05 0.80 0.26 
ASRB-4 0.09 -0.53 0.71 0.78 0.28 
ASRB-5 0.30 -0.23 0.82 0.27 1.10 
EDIN 0.93 0.15 1.71 0.02 2.32 
Dublin 0.11 -0.47 0.69 0.71 0.37 
Galway 0.14 -0.82 1.09 0.78 0.28 
HUBIN 0.53 -0.12 1.18 0.11 1.60 
MCPR 1.03 0.36 1.70 0.00 3.01 
TOP 0.28 -0.04 0.60 0.09 1.69 
MCIC 0.53 0.18 0.87 <0.01 3.00 
COBRE 0.40 0.05 0.74 0.03 2.22 
Madrid 0.20 -0.24 0.64 0.37 0.89 
Oxford 0.23 -0.40 0.87 0.47 0.72 
mean 0.35 0.23 0.48 <0.001 5.57 
Overall 
 
0.37 0.27 0.47 <0.001 7.20 
 
Supplementary table 9. Meta-analysis results for gFA and IQ in males & females. There was no 
significant difference in the observed Hedges’ g effect size for males (ES=0.35, CI=0.23-0.48) and 
females (ES=0.39, CI=0.22-0.55), x2(1)=0.09 p=0.77. CI=95% confidence intervals. 
 
 
Site Hedge's g CI Lower CI Upper p z 
Female 
ASRB-1 0.46 -0.14 1.05 0.13 1.51 
ASRB-2 0.27 -0.22 0.75 0.28 1.08 
ASRB-3 0.10 -1.08 1.29 0.86 0.17 
ASRB-4 0.00 -0.84 0.84 1.00 0.00 
ASRB-5 0.26 -0.38 0.89 0.43 0.80 
EDIN 0.25 -0.62 1.11 0.58 0.56 
Dublin 0.09 -0.57 0.74 0.79 0.26 
HUBIN 0.82 -2.47 4.11 0.63 0.49 
MCPR 0.37 -0.70 1.44 0.50 0.67 
TOP 0.09 -0.45 0.63 0.75 0.32 
MCIC 0.76 0.36 1.17 <0.0001 3.67 
COBRE 0.90 0.36 1.44 <0.01 3.28 
Madrid 0.18 -0.44 0.79 0.58 0.56 
Oxford 0.28 -0.36 0.92 0.39 0.85 
Oxford 0.11 -0.57 0.78 0.75 0.31 
mean 0.37 0.20 0.53 <0.001 4.37 
Male 
ASRB-1 0.46 0.06 0.85 0.02 2.25 
ASRB-2 0.36 -0.05 0.78 0.09 1.70 
ASRB-3 0.12 -0.80 1.05 0.80 0.26 
ASRB-4 0.00 -0.62 0.62 1.00 0.00 
ASRB-5 0.26 -0.26 0.78 0.33 0.97 
EDIN 0.83 0.06 1.60 0.03 2.13 
Dublin 0.15 -0.43 0.73 0.61 0.51 
Galway 0.06 -0.89 1.01 0.90 0.13 
HUBIN 0.55 -0.11 1.20 0.10 1.64 
MCPR 0.99 0.33 1.66 <0.01 2.93 
TOP 0.21 -0.11 0.53 0.20 1.29 
MCIC 0.54 0.19 0.88 <0.01 3.05 
COBRE 0.33 -0.02 0.68 0.06 1.87 
Madrid 0.00 -0.44 0.44 1.00 0.00 
Oxford 0.23 -0.41 0.86 0.48 0.70 
mean 0.33 0.21 0.46 <0.001 5.23 
Overall 
 
0.35 0.25 0.45 <0.001 6.81 
 
Supplementary table 10. Meta-analysis results for LAgFA and IQ in males & females. There was no 
significant difference in the observed Hedges’ g effect size for males (ES=0.33, CI=0.21-0.46) and 








CI lower CI upper p 
MD 
HC 397 0.25 0.05 0.46 0.01 
Sz 467 0.19 0.00 0.38 0.05 
All 864 0.22 0.08 0.36 <0.01 
RD 
HC 397 0.37 0.02 0.72 0.04 
Sz 467 0.31 0.07 0.55 0.01 
All 864 0.33 0.13 0.52 <0.01 
AD 
HC 397 0.32 0.11 0.52 <0.01 
Sz 467 0.07 -0.12 0.25 0.47 
All 864 0.24 0.11 0.37 0.01 
LA-gMD 
HC 397 0.19 -0.01 0.34 0.07 
Sz 467 0.09 -0.09 0.28 0.33 
All 864 0.14 0.00 0.27 0.05 
LA-gRD 
HC 397 0.27 -0.08 0.62 0.13 
Sz 467 0.42 0.04 0.80 0.03 
All 864 0.34 0.08 0.60 0.01 
LA-gAD 
HC 397 0.28 0.08 0.48 0.01 
Sz 467 0.14 -0.05 0.32 0.15 
All 864 0.20 0.06 0.34 <0.01 
 
 Supplementary table 11. Meta-analysis results for secondary diffusion MRI parameters. MD=mean 
diffusivity, RD=radial diffusivity, AD=axial diffusivity, LA=long association tract analysis. The largest 
effect sizes were observed for measures relating to radial diffusivity (RD & LA-gRD).  
 
 
 ASRB EDIN Dublin HUBIN MPRC Galway 
gFA 0.057 0.369 0.037 0.251 0.273 0.193 
gMD -0.053 -0.106 -0.221 -0.344 -0.01 -0.173 
gRD -0.105 -0.245 -0.153 -0.347 -0.423 -0.197 
gAD 0.049 0.195 -0.296 -0.153 -0.101 -0.049 
LA-gFA 0.139 0.344 0.079 0.253 0.229 0.064 
LA-gMD -0.12 -0.158 -0.135 -0.28 -0.021 -0.077 
LA-gRD -0.063 -0.265 -0.131 -0.324 -0.385 -0.064 
LA-gAD 0.088 0.164 -0.114 -0.115 -0.094 -0.033 
 
Supplementary table 12. Per-Site Regression Standardized Beta Coefficients for secondary diffusion 
MRI parameters. The standardized Beta’s reported here support our findings that higher FA is 
associated with higher cognitive functions, which is primarily driven by increased radial diffusivity.  
 
 
Supplementary Figure 1a. 
 
Supplementary Figure 1b. 
 
 
White matter tract PCA loading for each site, across site mean, standard deviation and % coefficient of v
ASRB-1 ASRB-2 ASRB-3 ASRB-4 ASRB-5 EDIN Dublin
CR 0.94 0.93 0.90 0.96 0.90 0.93 0.92
CC 0.92 0.91 0.91 0.94 0.86 0.85 0.80
ACR 0.86 0.85 0.86 0.86 0.84 0.80 0.85
GCC 0.85 0.87 0.81 0.91 0.85 0.85 0.80
IC 0.81 0.84 0.85 0.85 0.80 0.84 0.79
PCR 0.86 0.80 0.80 0.88 0.78 0.86 0.75
EC 0.83 0.77 0.83 0.79 0.80 0.81 0.71
SLF 0.78 0.79 0.81 0.77 0.64 0.76 0.80
BCC 0.85 0.77 0.84 0.85 0.71 0.71 0.72
ALIC 0.77 0.78 0.84 0.70 0.66 0.77 0.74
PTR 0.82 0.80 0.83 0.66 0.80 0.79 0.64
SCR 0.79 0.79 0.75 0.89 0.65 0.85 0.76
SS 0.77 0.78 0.76 0.58 0.70 0.76 0.71
SCC 0.81 0.78 0.76 0.78 0.75 0.77 0.53
CGC 0.77 0.78 0.82 0.78 0.79 0.74 0.66
SFO 0.71 0.64 0.75 0.64 0.57 0.72 0.65
FXST 0.63 0.58 0.51 0.65 0.65 0.74 0.51
UNC 0.52 0.41 0.49 0.56 0.43 0.62 0.36
FX 0.62 0.52 0.63 0.56 0.62 0.50 0.41
ASRB-1 ASRB-2 ASRB-3 ASRB-4 ASRB-5 EDIN Dublin
CR 0.93 0.93 0.92 0.96 0.90 0.95 0.92
ACR 0.82 0.80 0.86 0.86 0.80 0.81 0.85
PCR 0.83 0.85 0.79 0.92 0.79 0.87 0.74
IC 0.69 0.84 0.82 0.80 0.90 0.84 0.81
CC 0.84 0.90 0.93 0.94 0.85 0.86 0.75
GCC 0.68 0.88 0.78 0.91 0.84 0.86 0.75
EC 0.77 0.74 0.85 0.86 0.77 0.83 0.65
PTR 0.75 0.80 0.74 0.72 0.72 0.81 0.63
SLF 0.75 0.78 0.85 0.79 0.73 0.72 0.78
ALIC 0.50 0.75 0.84 0.61 0.72 0.77 0.74
SCR 0.70 0.83 0.82 0.91 0.65 0.88 0.76
BCC 0.72 0.76 0.93 0.85 0.65 0.72 0.65
SCC 0.64 0.76 0.80 0.72 0.76 0.84 0.53
SS 0.60 0.72 0.68 0.52 0.62 0.76 0.64
SFO 0.50 0.68 0.91 0.79 0.63 0.75 0.58
CGC 0.73 0.75 0.84 0.76 0.68 0.72 0.66
FXST 0.59 0.64 0.37 0.72 0.58 0.76 0.47
UNC 0.45 0.55 0.35 0.78 0.47 0.59 0.27
FX 0.59 0.40 0.78 0.69 0.57 0.46 0.33
SS 0.94 0.92 0.88 0.96 0.89 0.90 0.92
CGC 0.92 0.91 0.87 0.94 0.86 0.83 0.86
FX 0.86 0.88 0.86 0.86 0.85 0.75 0.83
PTR 0.87 0.76 0.77 0.86 0.78 0.83 0.75
ALIC 0.88 0.87 0.82 0.92 0.85 0.84 0.86
SCC 0.83 0.79 0.86 0.76 0.81 0.76 0.79




FXST 0.86 0.77 0.73 0.86 0.74 0.68 0.81
ACR 0.80 0.83 0.81 0.66 0.72 0.74 0.82
UNC 0.80 0.81 0.81 0.75 0.61 0.77 0.75
EC 0.83 0.81 0.89 0.68 0.82 0.74 0.62
CC 0.80 0.76 0.71 0.87 0.64 0.83 0.76
IC 0.74 0.61 0.61 0.59 0.54 0.66 0.75
PCR 0.79 0.81 0.76 0.77 0.56 0.80 0.85
GCC 0.84 0.80 0.68 0.83 0.74 0.70 0.54
SFO 0.79 0.80 0.77 0.81 0.85 0.75 0.64
SCR 0.64 0.52 0.64 0.60 0.68 0.71 0.55
CR 0.54 0.28 0.53 0.45 0.42 0.64 0.51
BCC 0.63 0.60 0.49 0.46 0.65 0.48 0.40
ANOVA Reults comparing white matter tract loading between healthy controls and patients with schizo
Sum of Squdf Mean SquaF Sig.
ASRB_1 Between G 0.113 1 0.113 8.47 *0.006
Within Gro 0.482 36 0.013
Total 0.595 37
ASRB_2 Between G 0 1 0 0 0.996
Within Gro 0.715 36 0.02
Total 0.715 37
ASRB_3 Between G 0.007 1 0.007 0.317 0.577
Within Gro 0.738 36 0.021
Total 0.745 37
ASRB_4 Between G 0.01 1 0.01 0.559 0.46
Within Gro 0.662 36 0.018
Total 0.673 37
ASRB_5 Between G 0 1 0 0.031 0.86
Within Gro 0.54 36 0.015
Total 0.541 37
EDIN Between G 0.008 1 0.008 0.697 0.409
Within Gro 0.387 36 0.011
Total 0.395 37
Dublin Between G 0.047 1 0.047 1.958 0.17
Within Gro 0.873 36 0.024
Total 0.92 37
HUBIN Between G 0.112 1 0.112 4.203 *0.048
Within Gro 0.96 36 0.027
Total 1.072 37
MCPR Between G 0.002 1 0.002 0.403 0.529
Within Gro 0.158 36 0.004
Total 0.159 37
TOP Between G 0.003 1 0.003 0.118 0.734
Within Gro 1.016 36 0.028
Total 1.019 37
MCIC Between G 0.003 1 0.003 0.186 0.669
Within Gro 0.628 36 0.017
Total 0.632 37
Sz
COBRE Between G 0.009 1 0.009 0.45 0.507
Within Gro 0.708 36 0.02
Total 0.717 37
Madrid Between G 0 1 0 0 1
Within Gro 1.223 36 0.034
Total 1.223 37
Oxford Between G 0.04 1 0.04 2.052 0.161
Within Gro 0.707 36 0.02
Total 0.748 37
*p value does not survive Bonferroni correction for multiple comparisons
                 variance
HUBIN MCPR TOP MCIC COBRE Madrid Oxford Average SD
0.90 0.94 0.86 0.94 0.90 0.92 0.92 0.92 0.03
0.80 0.92 0.83 0.94 0.83 0.87 0.88 0.88 0.05
0.80 0.90 0.76 0.89 0.85 0.82 0.88 0.84 0.04
0.80 0.88 0.73 0.91 0.78 0.72 0.85 0.83 0.06
0.76 0.85 0.76 0.92 0.84 0.84 0.82 0.83 0.04
0.81 0.87 0.78 0.80 0.80 0.83 0.84 0.82 0.04
0.71 0.84 0.69 0.86 0.70 0.82 0.83 0.78 0.06
0.82 0.86 0.78 0.94 0.86 0.55 0.83 0.78 0.09
0.60 0.84 0.72 0.87 0.78 0.81 0.76 0.77 0.08
0.67 0.83 0.68 0.91 0.82 0.78 0.81 0.77 0.07
0.81 0.83 0.65 0.86 0.75 0.70 0.73 0.76 0.07
0.63 0.80 0.61 0.68 0.73 0.83 0.79 0.75 0.08
0.83 0.85 0.71 0.87 0.81 0.69 0.61 0.75 0.09
0.70 0.85 0.61 0.91 0.58 0.78 0.80 0.74 0.10
0.65 0.88 0.63 0.86 0.72 0.51 0.69 0.73 0.10
0.65 0.78 0.65 0.79 0.70 0.73 0.73 0.69 0.06
0.52 0.74 0.40 0.81 0.53 0.58 0.59 0.60 0.11
0.57 0.71 0.41 0.73 0.58 0.38 0.61 0.53 0.12
0.24 0.81 0.19 0.46 0.40 0.51 0.44 0.49 0.16
HUBIN MCPR TOP MCIC COBRE Madrid Oxford Average SD
0.87 0.94 0.88 0.93 0.91 0.91 0.90 0.92 0.03
0.76 0.90 0.76 0.88 0.82 0.83 0.82 0.83 0.04
0.73 0.86 0.77 0.77 0.80 0.80 0.81 0.81 0.05
0.74 0.85 0.77 0.92 0.81 0.84 0.83 0.82 0.06
0.76 0.94 0.82 0.93 0.84 0.93 0.88 0.87 0.06
0.79 0.91 0.73 0.89 0.79 0.81 0.83 0.82 0.07
0.71 0.87 0.68 0.83 0.75 0.81 0.82 0.78 0.07
0.80 0.85 0.65 0.85 0.64 0.66 0.66 0.73 0.08
0.72 0.83 0.78 0.93 0.81 0.55 0.81 0.77 0.09
0.66 0.85 0.69 0.90 0.77 0.76 0.70 0.73 0.10
0.58 0.79 0.63 0.59 0.80 0.87 0.74 0.75 0.11
0.51 0.88 0.72 0.85 0.75 0.86 0.81 0.76 0.11
0.66 0.83 0.63 0.87 0.55 0.82 0.78 0.73 0.11
0.78 0.84 0.72 0.88 0.78 0.86 0.48 0.71 0.12
0.52 0.81 0.66 0.75 0.74 0.85 0.59 0.70 0.12
0.48 0.90 0.59 0.86 0.68 0.29 0.60 0.68 0.16
0.36 0.71 0.40 0.79 0.41 0.62 0.61 0.57 0.15
0.60 0.71 0.40 0.65 0.60 0.32 0.57 0.52 0.15
0.12 0.83 0.17 0.42 0.34 0.62 0.41 0.48 0.21
0.92 0.94 0.85 0.93 0.90 0.91 0.95 0.91 0.03
0.81 0.89 0.84 0.94 0.82 0.93 0.88 0.88 0.04
0.88 0.90 0.79 0.88 0.86 0.83 0.95 0.86 0.05
0.86 0.92 0.81 0.81 0.80 0.80 0.85 0.82 0.05
0.83 0.81 0.73 0.89 0.77 0.81 0.87 0.84 0.05
0.72 0.79 0.73 0.88 0.67 0.81 0.84 0.79 0.06
0.80 0.87 0.68 0.91 0.87 0.84 0.80 0.83 0.06
0.66 0.76 0.72 0.86 0.79 0.86 0.73 0.77 0.07
0.89 0.87 0.65 0.85 0.84 0.86 0.69 0.79 0.08
0.69 0.78 0.61 0.89 0.85 0.76 0.88 0.77 0.08
0.82 0.82 0.62 0.84 0.81 0.66 0.78 0.77 0.09
0.66 0.85 0.53 0.74 0.72 0.87 0.84 0.75 0.10
0.76 0.72 0.57 0.79 0.69 0.85 0.81 0.69 0.10
0.91 0.92 0.76 0.93 0.89 0.55 0.84 0.80 0.12
0.75 0.88 0.50 0.93 0.58 0.82 0.84 0.74 0.13
0.74 0.83 0.70 0.86 0.75 0.29 0.78 0.74 0.14
0.64 0.80 0.29 0.80 0.58 0.62 0.52 0.61 0.13
0.55 0.72 0.44 0.76 0.56 0.32 0.64 0.52 0.14
0.33 0.76 0.28 0.35 0.43 0.62 0.40 0.49 0.14
             phrenia
CV-%
3
6
5
7
5
5
7
12
10
9
10
11
11
14
14
9
18
23
32
CV-%
3
5
7
7
7
9
9
11
11
14
14
15
15
17
18
23
26
29
44
3
5
5
6
6
7
7
9
10
11
11
13
14
15
18
19
21
26
29
